By Jared S. Hopkins
Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, including building four new plants.
The North Chicago, Ill.-based pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.S. presence as the threat of tariffs looms over the industry.
Chief Executive Rob Michael told analysts Friday the company is working to mitigate the impact of any tariffs through possible supply chain actions, cost efficiencies, and expanding domestic manufacturing beyond 11 U.S. sites. AbbVie doesn't plan to pass price increases onto customers, he said.
AbbVie estimated a $30 million impact due to existing tariffs, which the company is absorbing, AbbVie said.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
April 25, 2025 12:02 ET (16:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。